Adocia SA (ADOC.PA)
Develops faster-acting insulin formulations and obesity treatments using a molecular delivery platform.
3.96+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-40.9%
The outlook
Adocia trades near its 52-week low, sitting below both its 50- and 200-day moving averages. Analysts lean bullish with a buy consensus, and their average price target sits roughly 145% above the current price. The stock's technical position remains weak despite the optimistic analyst view.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range4% of the way from its 52-week low to high
Price targetAvg target +145% vs current price
Analyst price target
~12-month · 4 analysts9.70average target+144.9% vs now
Now 3.96
Low 4.80High 12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$79.2M
52-wk high
12.40
52-wk low
3.61
50-day avg
4.23
200-day avg
5.94
Trailing P/E
—